WO2017010109A1 - Séquence de base pour l'expression de protéine et procédé de production de protéine utilisant celle-ci - Google Patents

Séquence de base pour l'expression de protéine et procédé de production de protéine utilisant celle-ci Download PDF

Info

Publication number
WO2017010109A1
WO2017010109A1 PCT/JP2016/003361 JP2016003361W WO2017010109A1 WO 2017010109 A1 WO2017010109 A1 WO 2017010109A1 JP 2016003361 W JP2016003361 W JP 2016003361W WO 2017010109 A1 WO2017010109 A1 WO 2017010109A1
Authority
WO
WIPO (PCT)
Prior art keywords
base sequence
promoter
gene
transcription factor
protein
Prior art date
Application number
PCT/JP2016/003361
Other languages
English (en)
Inventor
Satoru Shinkawa
Shigenobu Mitsuzawa
Maiko Tanaka
Masayuki Machida
Hiroko Hagiwara
Hideaki Koike
Mahoko KUNINAGA
Original Assignee
Honda Motor Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Honda Motor Co., Ltd. filed Critical Honda Motor Co., Ltd.
Priority to EP16747632.4A priority Critical patent/EP3322808B1/fr
Priority to US15/745,070 priority patent/US10266833B2/en
Publication of WO2017010109A1 publication Critical patent/WO2017010109A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/38—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Aspergillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)

Definitions

  • the present invention relates to a base sequence for protein expression for use in the production of protein such as diastatic enzyme using koji mold, and a method for producing protein using the same.
  • a base sequence for protein expression in which a cis element consisting of a particular base sequence is linked to a promoter of a particular gene that yields protein when producing protein such as a diastatic enzyme using koji mold (see e.g., Patent Literatures 1 and 2).
  • the conventional base sequence for protein expression can improve the activity of the promoter and can increase the yield of the protein, by linking the cis element to the promoter.
  • Patent Literature 1 describes a technique of using enhancer DNA consisting of a XlnR/Ace2 binding sequence and a Hap complex binding sequence as a cis element and linking 12 cis elements upstream (on the 5'-terminal side) of a promoter of tef1 gene. According to Patent Literature 1, in this way, GUS activity by the promoter is reported to be improved approximately 4.9 times under solid culture conditions with wheat bran as a carbon source.
  • the conventional base sequence for protein expression merely links a cis element consisting of a particular base sequence to a promoter of a particular gene and is thus desired to be further modified.
  • an object of the present invention is to provide a base sequence for protein expression that can increase the yield of protein such as diastatic enzyme by further activating a promoter of a particular gene, and a method for producing protein using the same.
  • the base sequence for protein expression of the present invention is a base sequence for protein expression comprising: a gene encoding protein; a promoter of the gene, the promoter being linked upstream of the gene; and a cis element whose activity is improved by an artificial transcription factor, the cis element being linked further upstream of the promoter, wherein the cis element is represented by SEQ ID NO: 1.
  • the activity of the cis element represented by SEQ ID NO: 1 linked upstream of the promoter can be improved by the artificial transcription factor, and the activity of the promoter can be further improved by the cis element whose activity has been improved.
  • the activity of the gene is improved by the promoter whose activity has been improved, so that the yield of the protein encoded by the gene can be increased.
  • the base sequence for protein expression of the present invention preferably comprises a base sequence for artificial transcription factor expression comprising: a gene encoding the artificial transcription factor represented by SEQ ID NO: 2; and a promoter of the gene, the promoter being linked upstream of the gene. According to the base sequence for artificial transcription factor expression, the activity of the gene encoding the artificial transcription factor represented by SEQ ID NO: 2 is improved by the promoter of the gene so that the artificial transcription factor encoded by the gene is produced.
  • the base sequence for protein expression of the present invention it is required that at least one cis element represented by SEQ ID NO: 1 should be linked upstream of the promoter.
  • the cis element is linked, for example, at any number in a range of 1 to 10, upstream of the promoter.
  • the expression vector of the present invention comprises the base sequence for protein expression of the present invention. According to the expression vector of the present invention, a transformant comprising the base sequence for protein expression of the present invention can be produced.
  • koji mold should be used as a host cell, and it is more preferred that the koji mold should be an Aspergillus oryzae HO2 strain (National Institute of Technology and Evaluation, Patent Microorganisms Depositary, #122, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba, Japan, Deposition Date: November 12, 2013, Deposition No.: NITE BP-01750).
  • Aspergillus oryzae HO2 strain National Institute of Technology and Evaluation, Patent Microorganisms Depositary, #122, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba, Japan, Deposition Date: November 12, 2013, Deposition No.: NITE BP-01750.
  • the method for producing a protein according to the present invention comprises culturing a transformant comprising the base sequence for protein expression of the present invention, and recovering the protein encoded by the gene expression-enhanced by the base sequence for protein expression, from the medium or the inside of the transformant after the culture.
  • the base sequence for protein expression of the present invention can increase the yield of the protein encoded by the gene, as mentioned above. Accordingly, when the transformant comprising the base sequence for protein expression of the present invention is cultured, the produced protein accumulates in the medium or the transformant after the culture. Therefore, the protein can be recovered.
  • FIG. 1 is an illustrative diagram schematically showing the configuration and effect of a base sequence for protein expression of the present invention.
  • FIG. 2 is an illustrative diagram schematically showing a predicted structure of a transcription factor KojR.
  • FIG. 3 is an illustrative diagram schematically showing a predicted structure of a transcription factor AmyR.
  • FIG. 4 is a graph showing a relative value of GUS activity when a transformant of the present invention was cultured for 60 hours with dextrin as a substrate.
  • FIG. 5 is a graph showing GUS activity when the transformant of the present invention was cultured for 90 hours with dextrin as the substrate.
  • FIG. 6 is a graph showing GUS activity when the transformant of the present invention was cultured for 60 hours with glucose as a substrate.
  • a base sequence 1 for protein expression of the present embodiment comprises: a protein gene 3 encoding a desired protein 2; a promoter 4 linked upstream (on the 5'-terminal side) of the protein gene 3; and a cis element 5 linked upstream (on the 5'-terminal side) of the promoter 4.
  • the base sequence 1 for protein expression also comprises a base sequence 9 for artificial transcription factor expression comprising: an artificial transcription factor gene 7 encoding an artificial transcription factor 6; and a promoter 8 linked upstream (on the 5'-terminal side) of the artificial transcription factor gene 7.
  • the activity of the cis element 5 is improved by the artificial transcription factor 6.
  • the artificial transcription factor 6 is prepared from a transcription factor KojR 11 shown in FIG. 2 and a transcription factor AmyR 21 shown in FIG. 3.
  • the transcription factors KojR 11 and AmyR 21 are transcription factors both classified into Cys6 cysteine-Zinc cluster type, among transcription factors having a zinc-coordinating DNA binding domain (Zn_Cluster).
  • a DNA binding domain associated with binding to the cis element 5 is predicted to reside in a region 14 comprising the upstream Zn_Cluster 12.
  • Examples of a candidate region of the DNA binding domain can include a region composed of a base sequence of 1 to 118 aa, a region composed of a base sequence of 1 to 195 aa, and a region composed of a base sequence of 1 to 239 aa.
  • the transcription factor AmyR 21 comprises upstream (5'-terminal side) Zn_Cluster 22 and comprises a downstream (3'-terminal side) region 23 comprising an active domain.
  • the transcription factor AmyR 21 is composed of a base sequence of 604 aa in full length.
  • the Zn_Cluster 22 is composed of a base sequence of 13 to 52 aa.
  • Examples of a candidate region of the active domain in the transcription factor AmyR 21 can include a region composed of a base sequence of 113 to 604 aa, a region composed of a base sequence of 150 to 604 aa, a region composed of base sequence of 219 to 604 aa, and a region composed of a base sequence of 257 to 604 aa.
  • the artificial transcription factor of the present embodiment has a configuration (SEQ ID NO: 2) in which an active domain comprising a base sequence of downstream 113 to 604 aa of the transcription factor AmyR is linked downstream of a DNA binding domain comprising a base sequence of upstream 1 to 118 aa of the transcription factor KojR.
  • the artificial transcription factor 6 encoded by the artificial transcription factor gene 7 whose activity has been improved by the promoter 8 in the base sequence 9 for artificial transcription factor expression is produced, and the produced artificial transcription factor 6 binds to the cis element 5.
  • the activity of the cis element 5 is improved by the binding to the artificial transcription factor 6.
  • the activity of the promoter 4 is improved by the cis element 5 whose activity has been improved.
  • the activity of the protein gene 3 is improved by the promoter 4 whose activity has been improved, so that the protein 2 encoded by the protein gene 3 whose activity has been improved, is produced.
  • the base sequence 1 for protein expression of the present embodiment can increase the yield of the protein 2.
  • the genomic DNA gene of an Aspergillus oryzae HO2 strain (National Institute of Technology and Evaluation, Patent Microorganisms Depositary, #122, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba, Japan, Deposition Date: November 12, 2013, Deposition No.: NITE BP-01750) was used as a template in PCR to amplify an upstream sequence of tppA gene using primers 1 and 2, its downstream sequence using primers 3 and 4, a tef1 promoter gene using primers 5 and 6, an agdA terminator gene using primers 7 and 8, and a gene fragment for marker recycling using primers 9 and 10, while the genomic DNA gene of an Aspergillus awamori HA1 strain (National Institute of Technology and Evaluation, Patent Microorganisms Depositary, #122, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba, Japan, Deposition Date: November 12, 2013, Deposition No.
  • DNA polymerase (manufactured by Toyobo Co., Ltd., product name: KOD FX neo) was used in each PCR amplification.
  • the amplification products were each purified using a purification kit (manufactured by Qiagen N.V., product name: QIAquick PCR purification kit) to obtain a total of 6 gene fragments.
  • an E. coli-derived plasmid pMD20 (manufactured by Takara Bio Inc.) was used as a template in PCR to amplify a gene fragment derived from the plasmid using primers 13 and 14 and the DNA polymerase.
  • the amplification product was purified using the purification kit to obtain the gene fragment.
  • the plasmid pPT was treated with a restriction enzyme SmaI (manufactured by Takara Bio Inc.) at 30°C and purified using the purification kit to obtain the restriction treatment product of the plasmid (gene fragment).
  • SmaI restriction enzyme manufactured by Takara Bio Inc.
  • the genomic DNA gene of an Aspergillus oryzae HO2 strain (National Institute of Technology and Evaluation, Patent Microorganisms Depositary, #122, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba, Japan, Deposition Date: November 12, 2013, Deposition No.: NITE BP-01750) was used as a template in PCR to amplify a DNA binding domain of a transcription factor KojR using primers 15 and 16 and an active domain of a transcription factor AmyR using primers 17 and 18.
  • the DNA polymerase was used in each PCR amplification.
  • the amplification products were each purified using the purification kit to obtain the DNA binding domain and the active domain.
  • the DNA binding domain and the active domain were treated with the cloning kit and used in the transformation of an E. coli HST08 strain to construct a plasmid carrying an artificial transcription factor gene in which the DNA binding domain and the active domain were joined together.
  • the plasmid carrying the artificial transcription factor gene was used as a template in PCR to amplify a gene fragment for koji mold transformation using primers 19 and 20 using DNA polymerase (manufactured by Toyobo Co., Ltd., product name: KOD-plus-neo).
  • the amplification product was purified using the purification kit to obtain the gene fragment for koji mold transformation.
  • an Aspergillus oryzae HO2 strain (National Institute of Technology and Evaluation, Patent Microorganisms Depositary, #122, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba, Japan, Deposition Date: November 12, 2013, Deposition No.: NITE BP-01750) was transformed with the gene fragment for koji mold transformation according to the standard method of the PEG-calcium technique. Subsequently, the obtained transformants were screened for a strain capable of growing in a CD plate medium to obtain a transcription factor-producing strain.
  • the transcription factor-producing strain was inoculated at 1 ⁇ 10 6 cells/plate to a CD medium supplemented with fluoroorotic acid monohydrate (manufactured by Wako Pure Chemical Industries, Ltd.) (final concentration: 1 mg/mL) and uridine (manufactured by Sigma-Aldrich Inc.) (final concentration: 20 mM) and screened for a strain capable of growing therein to obtain a uridine-auxotrophic transcription factor-producing strain.
  • fluoroorotic acid monohydrate manufactured by Wako Pure Chemical Industries, Ltd.
  • uridine manufactured by Sigma-Aldrich Inc.
  • the base sequences of the primers 1 to 20 are shown in Table 1.
  • the first gene fragment and a plasmid pPEA2 containing an Aspergillus oryzae-derived enoA promoter were each fragmented by treatment with restriction enzymes SphI and NcoI. These fragments were subjected to ligation reaction, and E. coli was then transformed with the ligation product to construct a plasmid pEA4K.
  • the gene fragment was treated with a restriction enzyme BamHI, while the plasmid pEA4K was treated with restriction enzymes BglII and NcoI. These two treatment products were subjected to ligation reaction, and E. coli was then transformed with the ligation product to construct a plasmid pEA8K.
  • the plasmid pEA8K was used as a template in PCR amplification using primers 21 and 22 and DNA polymerase (manufactured by Toyobo Co., Ltd., product name: KOD-plus-).
  • the amplification product was purified using a purification kit (manufactured by Promega Corp., product name: Wizard SV Gel and PCR Clean-Up System) to obtain a second gene fragment.
  • genomic DNA of Aspergillus oryzae was used as a template in PCR amplification using primers 23 and 24 and DNA polymerase (manufactured by Toyobo Co., Ltd., product name: KOD-plus-).
  • the amplification product was purified using a purification kit (manufactured by Promega Corp., product name: Wizard SV Gel and PCR Clean-Up System) to obtain a third gene fragment.
  • the second gene fragment and the third gene fragment were used as a template in fusion PCR using primers 22 and 24 to prepare a fourth gene fragment in which the second gene fragment and the third gene fragment were joined together.
  • a restriction enzyme-treated plasmid pPPG introduced with an E. coli-derived plasmid pMD20 (manufactured by Takara Bio Inc.) carrying upstream 1000 bp of Aspergillus oryzae-derived pyrG gene, an Aspergillus oryzae-derived pyrG expression cassette, and an E.
  • coli-derived uidA gene was subjected to ligation reaction with a gene fragment for marker recycling obtained by PCR-amplifying a plasmid pPPG as a template using primers 25 and 26 and DNA polymerase (manufactured by Toyobo Co., Ltd., product name: KOD-plus-) and purifying the amplification product using a purification kit (manufactured by Promega Corp., product name: Wizard SV Gel and PCR Clean-Up System). Then, E. coli was transformed with the ligation product to construct a plasmid pPPRG.
  • a gene fragment for marker recycling obtained by PCR-amplifying a plasmid pPPG as a template using primers 25 and 26 and DNA polymerase (manufactured by Toyobo Co., Ltd., product name: KOD-plus-) and purifying the amplification product using a purification kit (manufactured by Promega Corp., product
  • the plasmid pPPRG was used as a template in PCR amplification using primers 27 and 28 and DNA polymerase (manufactured by Toyobo Co., Ltd., product name: KOD-plus-).
  • the amplification product was purified using a purification kit (manufactured by Promega Corp., product name: Wizard SV Gel and PCR Clean-Up System) to obtain a fifth gene fragment.
  • the fourth gene fragment and the fifth gene fragment were used as a template in fusion PCR using primers 24 and 27 to prepare a cis element-linked GUS ( ⁇ - glucuronidase) production cassette gene fragment in which the fourth gene fragment and the fifth gene fragment were joined together.
  • GUS ⁇ - glucuronidase
  • the uridine-auxotrophic transcription factor-producing strain was transformed using the cis element-linked GUS production cassette gene fragment according to the standard method of the PEG-calcium technique. Subsequently, the obtained transformants were screened for a strain capable of growing in a CD plate medium to obtain a GUS-producing strain with 8 cis elements linked in tandem.
  • the base sequences of the primers 21 to 28 are shown in Table 2.
  • the GUS-producing strain with 8 cis elements linked in tandem was cultured in a CD plate medium for 1 week to form spores.
  • the spores were recovered using 0.01% POLYSORBATE 20 (manufactured by Wako Pure Chemical Industries, Ltd.) to obtain a spore suspension.
  • a PD medium (2 mass/volume% of dextrin, 1 mass/volume% of polypeptone, 0.1 mass/volume% of casamino acid, 0.5 mass/volume% of potassium dihydrogen phosphate, 0.05 mass/volume% of magnesium sulfate, and 0.1 mass/volume% of sodium nitrate) was placed in a 200 mL Erlenmeyer flask, to which the spores were then inoculated at a final spore concentration of 1 ⁇ 10 5 /mL.
  • liquid culture was performed at 30°C for 60 hours. After the completion of the culture, the bacterial cells were disrupted, and the disrupted powder was suspended in a buffer for intracellular protein extraction having the composition given below to obtain an extract.
  • the extract was added to a buffer for GUS activity measurement having the composition given below and reacted at 37°C for 15 minutes. Then, the absorbance was measured at a wavelength of 415 nm to calculate an activity value (U).
  • U means the amount of the enzyme necessary for forming 1 mM PNP from PNP-Glucuronide (purine nucleoside phosphorylase-glucuronic acid inclusion) at 37°C for 1 minute.
  • composition of buffer for GUS activity measurement Composition of buffer for GUS activity measurement
  • GUS activity (U/mg) when the liquid culture was performed at 30°C for 90 hours is shown in FIG. 5.
  • a GUS-producing strain was constructed in totally the same way as in Example 1 except that the artificial transcription factor gene was not introduced and no cis element was linked.
  • FIG. 4 A relative value of GUS activity (U/mg) when the liquid culture was performed at 30 °Cfor 60 hours is shown in FIG. 4.
  • GUS activity (U/mg) when the liquid culture was performed at 30°C for 90 hours is shown in FIG. 5.
  • GUS activity (U/mg) was calculated in totally the same way as in Example 1 except that 50 mL of a PG medium (2 mass/volume% of glucose, 1 mass/volume% of polypeptone, 0.1 mass/volume% of casamino acid, 0.5 mass/volume% of potassium dihydrogen phosphate, 0.05 mass/volume% of magnesium sulfate, and 0.1 mass/volume% of sodium nitrate) was placed in a 200 mL Erlenmeyer flask, to which the spores of the GUS-producing strain harboring 8 cis elements linked in tandem obtained in Example 1 were then inoculated at a final spore concentration of 1 ⁇ 10 5 /mL, followed by liquid culture at 30°C for 60 hours. The results are shown in FIG. 6.

Abstract

L'invention concerne une séquence de base pour l'expression de protéine qui peut augmenter le rendement de protéine telle qu'une enzyme diastatique par activation supplémentaire d'un promoteur d'un gène particulier. Une séquence de base 1 pour l'expression de protéine comprend : un gène 3 codant pour une protéine 2 ; un promoteur 4 du gène 3, le promoteur étant lié en amont du gène 3 ; et un élément cis 5 dont l'activité est améliorée par un facteur de transcription artificielle 6, l'élément cis étant en outre lié en amont du promoteur 4. L'élément cis 5 est représenté par SEQ ID NO : 1.
PCT/JP2016/003361 2015-07-16 2016-07-15 Séquence de base pour l'expression de protéine et procédé de production de protéine utilisant celle-ci WO2017010109A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP16747632.4A EP3322808B1 (fr) 2015-07-16 2016-07-15 Séquence de base pour l'expression de protéine et procédé de production de protéine utilisant celle-ci
US15/745,070 US10266833B2 (en) 2015-07-16 2016-07-15 Nucleic acid sequence for protein expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015142213A JP6709590B2 (ja) 2015-07-16 2015-07-16 タンパク質生産用システム及びタンパク質の製造方法
JP2015-142213 2015-07-16

Publications (1)

Publication Number Publication Date
WO2017010109A1 true WO2017010109A1 (fr) 2017-01-19

Family

ID=56567652

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/003361 WO2017010109A1 (fr) 2015-07-16 2016-07-15 Séquence de base pour l'expression de protéine et procédé de production de protéine utilisant celle-ci

Country Status (4)

Country Link
US (1) US10266833B2 (fr)
EP (1) EP3322808B1 (fr)
JP (1) JP6709590B2 (fr)
WO (1) WO2017010109A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6709591B2 (ja) * 2015-07-16 2020-06-17 本田技研工業株式会社 タンパク質生産用システム及びタンパク質の製造方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0238023A2 (fr) * 1986-03-17 1987-09-23 Novo Nordisk A/S Procédé de production de produits protéiniques dans aspergillus oryzae et promoteur à utiliser dans aspergillus
JPH099968A (ja) * 1995-06-29 1997-01-14 Oozeki Kk 糸状菌のエンハンサーｄｎａ塩基配列およびその用途
WO1998001470A1 (fr) * 1996-07-05 1998-01-15 Novo Nordisk A/S Facteur de transcription
JP2012075369A (ja) 2010-09-30 2012-04-19 Toyota Motor Corp シス作用エレメント及びその利用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6473339B2 (ja) * 2015-02-05 2019-02-20 本田技研工業株式会社 麹菌変異株及び形質転換体
WO2017010107A1 (fr) * 2015-07-16 2017-01-19 Honda Motor Co., Ltd. Séquence de base pour l'expression d'une protéine et procédé de production d'une protéine l'utilisant
JP6709591B2 (ja) * 2015-07-16 2020-06-17 本田技研工業株式会社 タンパク質生産用システム及びタンパク質の製造方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0238023A2 (fr) * 1986-03-17 1987-09-23 Novo Nordisk A/S Procédé de production de produits protéiniques dans aspergillus oryzae et promoteur à utiliser dans aspergillus
JPH099968A (ja) * 1995-06-29 1997-01-14 Oozeki Kk 糸状菌のエンハンサーｄｎａ塩基配列およびその用途
JP3343567B2 (ja) 1995-06-29 2002-11-11 大関株式会社 糸状菌のエンハンサーｄｎａ塩基配列およびその用途
WO1998001470A1 (fr) * 1996-07-05 1998-01-15 Novo Nordisk A/S Facteur de transcription
JP2012075369A (ja) 2010-09-30 2012-04-19 Toyota Motor Corp シス作用エレメント及びその利用
US20130196374A1 (en) * 2010-09-30 2013-08-01 Toyota Jidosha Kabushiki Kaisha Cis-acting element and use thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199712, Derwent World Patents Index; AN 1997-126425, XP002762233 *
GOMI K ET AL: "Molecular cloning and characterization of a transcriptional activator gene, amyR, involved in the amylolytic gene expression in Aspergillus oryzae", BIOSCIENCE BIOTECHNOLOGY BIOCHEMISTRY, JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, AND AGROCHEMISTRY, TOKYO, JAPAN, vol. 64, no. 4, 1 April 2000 (2000-04-01), pages 816 - 827, XP002356326, ISSN: 0916-8451, DOI: 10.1271/BBB.64.816 *
MACPHERSON SARAH ET AL: "A fungal family of transcriptional regulators: the zinc cluster proteins.", MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS : MMBR SEP 2006, vol. 70, no. 3, September 2006 (2006-09-01), pages 583 - 604, XP002762234, ISSN: 1092-2172 *
MARUI JUNICHIRO ET AL: "Kojic acid biosynthesis in Aspergillus oryzae is regulated by a Zn(II)(2)Cys(6) transcriptional activator and induced by kojic acid at the transcriptional level.", JOURNAL OF BIOSCIENCE AND BIOENGINEERING JUL 2011, vol. 112, no. 1, July 2011 (2011-07-01), pages 40 - 43, XP002762231, ISSN: 1347-4421 *
TERABAYASHI Y ET AL: "Identification and characterization of genes responsible for biosynthesis of kojic acid, an industrially important compound from Aspergillus oryzae", FUNGAL GENETICS AND BIOLOGY, SAN DIEGO, CA, US, vol. 47, no. 12, 1 December 2010 (2010-12-01), pages 953 - 961, XP027492601, ISSN: 1087-1845, [retrieved on 20101112], DOI: 10.1016/J.FGB.2010.08.014 *
TSUBOI HIROKAZU ET AL: "Improvement of the Aspergillus oryzae enolase promoter (P-enoA) by the introduction of cis-element repeats.", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY JAN 2005, vol. 69, no. 1, January 2005 (2005-01-01), pages 206 - 208, XP002762232, ISSN: 0916-8451 *
TSUKAGOSHI NORIHIRO ET AL: "Regulation of the amylolytic and (hemi-)cellulolytic genes in aspergilli", JOURNAL OF GENERAL AND APPLIED MICROBIOLOGY, vol. 47, no. 1, February 2001 (2001-02-01), pages 1 - 19, XP002762235, ISSN: 0022-1260 *

Also Published As

Publication number Publication date
US20180201942A1 (en) 2018-07-19
EP3322808B1 (fr) 2018-12-26
JP2017023012A (ja) 2017-02-02
US10266833B2 (en) 2019-04-23
EP3322808A1 (fr) 2018-05-23
JP6709590B2 (ja) 2020-06-17

Similar Documents

Publication Publication Date Title
Horinouchi et al. Hormonal control by A-factor of morphological development and secondary metabolism in Streptomyces
Ruth et al. Variable production windows for porcine trypsinogen employing synthetic inducible promoter variants in Pichia pastoris
US10563209B2 (en) Base sequence for protein expression and method for producing protein using same
WO2017010107A1 (fr) Séquence de base pour l'expression d'une protéine et procédé de production d'une protéine l'utilisant
WO2017010109A1 (fr) Séquence de base pour l'expression de protéine et procédé de production de protéine utilisant celle-ci
EP3054004B1 (fr) Souche mutante d'aspergillus et transformant de celui-ci
JP5297656B2 (ja) 新規枯草菌変異株及びタンパク質の製造方法
JP4495904B2 (ja) 改変プロモーター
JP5498651B2 (ja) ジピコリン酸又はその塩の製造方法
JP6465470B2 (ja) 糖化酵素の生産方法、及び草木類バイオマスの糖化処理方法
JP6360787B2 (ja) 麹菌変異株及び形質転換体
JP6368968B2 (ja) 形質転換体の製造方法、糖化酵素の生産方法、及び草木類バイオマスの糖化処理方法
JP2009118783A (ja) 糸状菌タンパク質分泌生産の改善
JP2021093966A (ja) 糸状菌への遺伝子導入方法及びその利用
WO2023074901A1 (fr) Promoteur inductible à l'érythritol et procédé de production de substances cibles l'utilisant
US9862958B2 (en) Nucleotide sequence and a process thereof
EP4032900A1 (fr) Nouvelles enzymes et procédés pour des voies métaboliques associées à l'acide vanillique
US20110129894A1 (en) Secretion optimized microorganism
KR101736485B1 (ko) 포름산염으로부터 수소생산능이 증가된 써모코코스 돌연변이체 및 이를 이용한 수소생산방법
JP4817795B2 (ja) 低温誘導性プロモーター
JP2020000167A (ja) 低温菌を用いたイタコン酸の製造方法
JP2017063666A (ja) ヌクレアーゼｓ１の生産方法
JP2015136323A (ja) 麹菌変異株

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16747632

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15745070

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE